JP2022516045A5 - - Google Patents

Info

Publication number
JP2022516045A5
JP2022516045A5 JP2021536413A JP2021536413A JP2022516045A5 JP 2022516045 A5 JP2022516045 A5 JP 2022516045A5 JP 2021536413 A JP2021536413 A JP 2021536413A JP 2021536413 A JP2021536413 A JP 2021536413A JP 2022516045 A5 JP2022516045 A5 JP 2022516045A5
Authority
JP
Japan
Prior art keywords
molecule
protein molecule
epitope
nucleic acid
cell surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021536413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516045A (ja
JP7654546B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/000334 external-priority patent/WO2020126064A1/en
Publication of JP2022516045A publication Critical patent/JP2022516045A/ja
Publication of JP2022516045A5 publication Critical patent/JP2022516045A5/ja
Priority to JP2025046059A priority Critical patent/JP2025102831A/ja
Priority to JP2025046058A priority patent/JP2025094140A/ja
Application granted granted Critical
Publication of JP7654546B2 publication Critical patent/JP7654546B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021536413A 2018-12-21 2019-12-09 エピトープ結合タンパク質にコンジュゲート化されたサポニン Active JP7654546B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025046059A JP2025102831A (ja) 2018-12-21 2025-03-19 エピトープ結合タンパク質にコンジュゲート化されたサポニン
JP2025046058A JP2025094140A (ja) 2018-12-21 2025-03-19 エピトープ結合タンパク質にコンジュゲート化されたサポニン

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
NL2022283 2018-12-21
NL2022283 2018-12-21
NL2023468 2019-07-10
NL2023468 2019-07-10
NL2023568 2019-07-25
NL2023568 2019-07-25
PCT/EP2019/000334 WO2020126064A1 (en) 2018-12-21 2019-12-09 Saponin conjugated to epitope-binding proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2025046059A Division JP2025102831A (ja) 2018-12-21 2025-03-19 エピトープ結合タンパク質にコンジュゲート化されたサポニン
JP2025046058A Division JP2025094140A (ja) 2018-12-21 2025-03-19 エピトープ結合タンパク質にコンジュゲート化されたサポニン

Publications (3)

Publication Number Publication Date
JP2022516045A JP2022516045A (ja) 2022-02-24
JP2022516045A5 true JP2022516045A5 (cg-RX-API-DMAC10.html) 2023-01-11
JP7654546B2 JP7654546B2 (ja) 2025-04-01

Family

ID=71101079

Family Applications (11)

Application Number Title Priority Date Filing Date
JP2021536407A Active JP7652695B2 (ja) 2018-12-21 2019-12-09 生物活性な分子のクラスター
JP2021536411A Active JP7541008B2 (ja) 2018-12-21 2019-12-09 サポニンコンジュゲート
JP2021536414A Active JP7593925B2 (ja) 2018-12-21 2019-12-09 改善された抗体-オリゴヌクレオチドコンジュゲート
JP2021536413A Active JP7654546B2 (ja) 2018-12-21 2019-12-09 エピトープ結合タンパク質にコンジュゲート化されたサポニン
JP2021536412A Active JP7614094B2 (ja) 2018-12-21 2019-12-09 薬物コンジュゲート
JP2021536410A Active JP7502301B2 (ja) 2018-12-21 2019-12-09 改善された細胞標的化結合分子
JP2024199932A Pending JP2025015702A (ja) 2018-12-21 2024-11-15 改善された抗体-オリゴヌクレオチドコンジュゲート
JP2024230339A Pending JP2025041928A (ja) 2018-12-21 2024-12-26 薬物コンジュゲート
JP2025040440A Pending JP2025090776A (ja) 2018-12-21 2025-03-13 生物活性な分子のクラスター
JP2025046059A Pending JP2025102831A (ja) 2018-12-21 2025-03-19 エピトープ結合タンパク質にコンジュゲート化されたサポニン
JP2025046058A Pending JP2025094140A (ja) 2018-12-21 2025-03-19 エピトープ結合タンパク質にコンジュゲート化されたサポニン

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2021536407A Active JP7652695B2 (ja) 2018-12-21 2019-12-09 生物活性な分子のクラスター
JP2021536411A Active JP7541008B2 (ja) 2018-12-21 2019-12-09 サポニンコンジュゲート
JP2021536414A Active JP7593925B2 (ja) 2018-12-21 2019-12-09 改善された抗体-オリゴヌクレオチドコンジュゲート

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2021536412A Active JP7614094B2 (ja) 2018-12-21 2019-12-09 薬物コンジュゲート
JP2021536410A Active JP7502301B2 (ja) 2018-12-21 2019-12-09 改善された細胞標的化結合分子
JP2024199932A Pending JP2025015702A (ja) 2018-12-21 2024-11-15 改善された抗体-オリゴヌクレオチドコンジュゲート
JP2024230339A Pending JP2025041928A (ja) 2018-12-21 2024-12-26 薬物コンジュゲート
JP2025040440A Pending JP2025090776A (ja) 2018-12-21 2025-03-13 生物活性な分子のクラスター
JP2025046059A Pending JP2025102831A (ja) 2018-12-21 2025-03-19 エピトープ結合タンパク質にコンジュゲート化されたサポニン
JP2025046058A Pending JP2025094140A (ja) 2018-12-21 2025-03-19 エピトープ結合タンパク質にコンジュゲート化されたサポニン

Country Status (15)

Country Link
US (10) US20220023433A1 (cg-RX-API-DMAC10.html)
EP (16) EP4241847B1 (cg-RX-API-DMAC10.html)
JP (11) JP7652695B2 (cg-RX-API-DMAC10.html)
KR (9) KR102894465B1 (cg-RX-API-DMAC10.html)
CN (8) CN119950740A (cg-RX-API-DMAC10.html)
AU (10) AU2019400630B2 (cg-RX-API-DMAC10.html)
BR (2) BR112021012222A8 (cg-RX-API-DMAC10.html)
CA (7) CA3124065A1 (cg-RX-API-DMAC10.html)
DK (4) DK3897738T5 (cg-RX-API-DMAC10.html)
ES (6) ES3072667T3 (cg-RX-API-DMAC10.html)
IL (8) IL284280B1 (cg-RX-API-DMAC10.html)
MX (2) MX2021007449A (cg-RX-API-DMAC10.html)
PT (2) PT3897735T (cg-RX-API-DMAC10.html)
SG (8) SG11202106664PA (cg-RX-API-DMAC10.html)
WO (8) WO2020126064A1 (cg-RX-API-DMAC10.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
JP7373998B2 (ja) 2017-05-02 2023-11-06 コーネル・ユニバーシティー 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
US20220023433A1 (en) * 2018-12-21 2022-01-27 Sapreme Technologies B.V. Saponin Conjugates
BR112022001389A8 (pt) * 2019-07-25 2023-04-25 Univ Berlin Charite Derivados de saponina com janela terapêutica melhorada
EP3838910B1 (en) * 2019-12-18 2022-09-28 Freie Universität Berlin Efficient gene delivery tool with a wide therapeutic margin
CN113527497B (zh) * 2020-04-16 2022-06-10 上海洛启生物医药技术有限公司 抗Trop2纳米抗体及其应用
EP4171645A2 (en) * 2020-06-24 2023-05-03 Sapreme Technologies B.V. Hydrazone-based saponin derivatives
CA3183887A1 (en) * 2020-06-24 2021-12-30 Ruben POSTEL Combination comprising an adc or an aoc comprising a vhh, and a saponin or a ligand-saponin conjugate
EP4117730A1 (en) * 2020-06-24 2023-01-18 Sapreme Technologies B.V. Conjugate of saponin and single-domain antibody, pharmaceutical composition comprising said conjugate, therapeutic use thereof
JP7652807B2 (ja) * 2020-06-24 2025-03-27 サプリーム テクノロジーズ,ベー.フェー. 単一ドメイン抗体、サポニン及びエフェクター分子のコンジュゲート、それを含む医薬組成物、前記医薬組成物の治療的使用
EP4596052A3 (en) * 2020-06-24 2025-11-05 Sapreme Technologies B.V. Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
KR20230043113A (ko) * 2020-06-24 2023-03-30 사프렘 테크놀로지스 비.브이. 의약용 사포닌 유도체
US20230263897A1 (en) * 2020-06-24 2023-08-24 Sapreme Technologies B.V. Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
CA3183881A1 (en) * 2020-06-24 2021-12-30 Sapreme Technologies B.V. Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
WO2021261995A1 (en) * 2020-06-24 2021-12-30 Sapreme Technologies B.V. Combination of an antibody-drug conjugate and an antibody-saponin conjugate
US20240327829A1 (en) * 2020-09-10 2024-10-03 Sapreme Technologies B.V. Conjugate of saponin, oligonucleotide and galnac
WO2022055352A1 (en) * 2020-09-10 2022-03-17 Sapreme Technologies B.V. Semicarbazone-based saponin conjugate
EP4210761B8 (en) * 2020-09-10 2025-09-24 Sapreme Technologies B.V. Semicarbazone-based saponin conjugate
WO2022055351A1 (en) * 2020-09-10 2022-03-17 Sapreme Technologies B.V. Conjugate of saponin, oligonucleotide and galnac
WO2022072718A1 (en) 2020-09-30 2022-04-07 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
EP4251206A4 (en) * 2020-11-24 2025-12-24 Brickbio Inc PROTEIN DERIVATIVES CONTAINING UNNATURAL AMINO ACIDS AND BRANCHED BINDERS
US20240115712A1 (en) 2021-01-26 2024-04-11 Sapreme Technologies B.V. Semicarbazone-based saponin conjugate
WO2022178754A1 (en) * 2021-02-25 2022-09-01 Shanghai Allygen Biologics Co., Ltd. Targeting conjugates with therapeutic agents and oligonucleotides and uses thereof
WO2022265493A1 (en) * 2021-06-18 2022-12-22 Sapreme Technologies B.V. Conjugate of saponin, oligonucleotide and galnac
WO2023038517A1 (en) 2021-09-09 2023-03-16 Sapreme Technologies B.V. Semicarbazone-based saponin conjugate
WO2023121447A1 (en) * 2021-12-22 2023-06-29 Sapreme Technologies B.V. Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
EP4452281A1 (en) 2021-12-22 2024-10-30 Sapreme Technologies B.V. Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders
CA3240612A1 (en) 2021-12-22 2023-06-29 Miriam Verena Bujny Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
US20250082759A1 (en) 2021-12-22 2025-03-13 Sapreme Technologies B.V. Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders
WO2023249473A1 (ko) * 2022-06-24 2023-12-28 주식회사 피노바이오 하나의 항체에 2종의 약물-링커 접합체가 연결된 항체-약물 접합체
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
WO2024046622A1 (en) * 2022-09-01 2024-03-07 Sapreme Technologies B.V. Compositions of polyplexes and saponins
EP4331610A1 (en) * 2022-09-01 2024-03-06 Sapreme Technologies B.V. Polyplex-saponin covalent conjugate
EP4331609A1 (en) * 2022-09-01 2024-03-06 Sapreme Technologies B.V. Methods and compositions for enhanced polyplex delivery
CN116259371B (zh) * 2022-09-09 2026-02-17 江苏理工学院 化合物激素受体活性预测方法和装置
US20240280568A1 (en) * 2023-02-13 2024-08-22 Nautilus Subsidiary, Inc. Affinity reagents having artificial polymer scaffolds
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
JP2026522541A (ja) * 2023-05-18 2026-07-08 ヴィセリックス・インコーポレーティッド 生物製剤の時空間的に制御されたペイロード送達のための形質膜埋込み型システム
WO2024261042A1 (en) 2023-06-21 2024-12-26 Sapreme Technologies B.V. Conjugates of saponin and antisense oligonucleotides for use in the treatment of neurodegenerative diseases
JP2026521777A (ja) 2023-06-21 2026-07-01 サプリーム テクノロジーズ,ベー.フェー. 中枢神経系障害を処置するための医薬組成物
WO2025222234A1 (en) * 2024-04-24 2025-10-30 Starpharma Pty Ltd Targeted dendrimer conjugates
EP4684805A1 (en) * 2024-07-24 2026-01-28 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Selective antibody-drug conjugates for targeted cancer therapy
WO2026087678A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for renal disorders
WO2026087695A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for metabolic disorder
WO2026087680A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for cardiovascular disease
WO2026119464A1 (en) 2024-12-03 2026-06-11 Sapreme Technologies B.V. Treatment for cns-related disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058021A3 (en) 1981-02-06 1982-10-27 Beecham Group Plc Pharmaceutical compositions
US5591829A (en) 1987-05-29 1997-01-07 Matsushita; Shuzo Antibodies modified with toxic substance
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
US5856571A (en) 1995-06-07 1999-01-05 Cellpro, Incorporated Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto
NZ500779A (en) * 1997-05-20 2001-06-29 Galenica Pharmaceuticals Inc Triterpene saponin analogs having adjuvant and immunostimulatory activity
US6262029B1 (en) * 1998-08-14 2001-07-17 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003069997A1 (en) * 2002-02-04 2003-08-28 Corixa Corporation Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
US7112573B2 (en) * 2002-04-19 2006-09-26 Iowa Research, The University Foundation Isoflavone and triterpene glycosides from soybeans
CA2522213A1 (en) 2003-04-08 2004-10-28 Dante J. Marciani Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
ES2395818T3 (es) 2004-07-13 2013-02-15 Charite - Universitatsmedizin Berlin Composición que comprende un agente farmacológicamente activo acoplado a un componente específico de célula diana, y una saponina
EP1796537A4 (en) 2004-08-25 2012-03-07 Univ Michigan DENDRIMER BASED COMPOSITIONS AND METHOD FOR THEIR USE
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
CN101563090B (zh) 2006-11-20 2013-01-02 杜科姆公司 包含南美皂皮树皂苷的含脂质颗粒用于治疗癌症的用途
WO2008109105A2 (en) * 2007-03-06 2008-09-12 Flagship Ventures Methods and compositions for improved therapeutic effects with sirna
EP2282752A4 (en) * 2008-03-26 2011-06-15 Ca Nat Research Council SAPONIN EXTRACT FROM SAPONARIA SPP AND ITS USES
WO2009126913A1 (en) 2008-04-11 2009-10-15 Cedars-Sinai Medical Center Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery
WO2011054811A1 (en) 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
ES2661228T3 (es) * 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
US9125835B2 (en) * 2010-11-12 2015-09-08 Rutgers, The State University Of New Jersey Synergistic combinations to reduce particle dose for targeted treatment of cancer and its metastases
CN102652836A (zh) 2011-03-03 2012-09-05 华中科技大学同济医学院附属协和医院 靶向释药的抗癌蛋白质或多肽聚合物前药及其制备方法
MX2014007121A (es) 2011-12-14 2014-09-04 Seattle Genetics Inc Nuevos conjugados de principio activo-ligante (adc) y su uso.
US9775915B2 (en) 2012-11-26 2017-10-03 President And Fellows Of Harvard College Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof
WO2014163558A1 (en) * 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
GB201400994D0 (en) * 2014-01-21 2014-03-05 Ucl Business Plc Drug delivery system
ES2719584T3 (es) 2014-04-11 2019-07-11 Medimmune Llc Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína
WO2015184451A1 (en) 2014-05-30 2015-12-03 Memorial Sloan-Kettering Cancer Center Minimal saponin analogues, synthesis and use thereof
TW201617368A (zh) * 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗mfi2抗體及使用方法
CN106892957B (zh) * 2015-12-17 2018-11-16 广州中医药大学 一种齐墩果烷型三萜皂苷类化合物及其制备方法和应用
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
AU2016423814B2 (en) 2016-09-26 2023-11-23 Desert King Chile S.A. Production of biomass in ultra high density plantations
EP3652190B1 (en) 2017-07-11 2023-06-14 Freie Universität Berlin Novel uses of a saponin and method for its isolation
US20220023433A1 (en) 2018-12-21 2022-01-27 Sapreme Technologies B.V. Saponin Conjugates
BR112022001389A8 (pt) 2019-07-25 2023-04-25 Univ Berlin Charite Derivados de saponina com janela terapêutica melhorada
WO2022055352A1 (en) 2020-09-10 2022-03-17 Sapreme Technologies B.V. Semicarbazone-based saponin conjugate
CA3240612A1 (en) * 2021-12-22 2023-06-29 Miriam Verena Bujny Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders

Similar Documents

Publication Publication Date Title
JP7652695B2 (ja) 生物活性な分子のクラスター
Schwach et al. More than toxins—current prospects in designing the next generation of antibody drug conjugates
WO2021259507A1 (en) Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
US20230248844A1 (en) Combination comprising an adc or an aoc comprising a vhh, and a saponin or a ligand-saponin conjugate
JP2025090796A (ja) 単一ドメイン抗体、サポニン及びエフェクター分子のコンジュゲート、それを含む医薬組成物、前記医薬組成物の治療的使用
US20240229033A1 (en) Compositions for Inhibiting Growth of Targeted Cells
JP2023532003A5 (cg-RX-API-DMAC10.html)
CN116249553A (zh) 抗体-药物缀合物和抗体-皂苷缀合物的组合
US20250295800A1 (en) Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
CN121219012A (zh) 用于治疗癌症的双有效载荷抗体药物缀合物
RU2021121380A (ru) Улучшенная клеточно-таргетная связующая молекула
NZ778372B2 (en) Biologically active cluster of molecules
Zaro et al. Summary and Future Directions of Antibody-Drug Conjugates
RU2021121414A (ru) Биологически активный кластер молекул
HK40130827A (en) Combination comprising an adc or an aoc comprising a vhh, and a saponin or a ligand-saponin conjugate